| Literature DB >> 35813433 |
Run Guo1, Tingting Wu1, Nan Zheng1, Yanfang Wan1, Jun Wang1.
Abstract
Tumour necrosis factor (TNF) levels are higher in patients who have experienced an acute ischemic stroke. Greater levels of TNF may not be linked to an increased risk of recurrent coronary events in the stable phase after myocardial ischemia (MI). Coronary atheroma is connected to endothelial and smooth muscle cells, as well as macrophages that emit the multifunctional cytokine tumour necrosis factor (TNF). Transplanted tumours become more vulnerable when TNF-α was first recognized to have a function in hemorrhagic necrosis. TNF-α has been demonstrated to induce heart failure, pulmonary edoema, and cardiomyopathy in people with advanced heart failure when it is elevated in the bloodstream. It has been postulated that prolonged overexpression of TNF-α after ischemia may contribute to poor cardiac outcomes by increasing TNF-α when the myocardium undergoes both temporary ischemia and reperfusion. A rise in TNF levels has been seen after a myocardial infarction, but it is unclear if these higher levels, found months after the initial event, are associated with an increased risk of subsequent heart attacks. We looked at TNF levels in the blood of 270 patients with coronary heart disease in the Chinese Hypertension League's Cholesterol and Recurrent Events (CARE) experiment to see if this notion held true. Recurrent coronary syndrome and coronary mortality were monitored prospectively in the participants. The min max imbalance normalization can be used to assess a patient's baseline characteristics, including hormone and cholesterol test results. Type 2 stimulant connection to aggregate the TNF-signaling qualities and fuzzy techniques was applied. There may now be enough preliminary evidence from the crucial bundle neural network analysis to identify the risk of coronary heart disease associated with TNF pregeneration studies. The tests were assessed using a variety of methods and performance metrics in a Matlab environment.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35813433 PMCID: PMC9262531 DOI: 10.1155/2022/3439768
Source DB: PubMed Journal: Comput Math Methods Med ISSN: 1748-670X Impact factor: 2.809
Figure 1TNF-α production.
Figure 2Schematic representation of the suggested methodology.
Patient characteristics.
| Total number of cases | Control patients | Value of | |
|---|---|---|---|
| Age in years | 50.11 ± 10.80 | 60.00 ± 9.44 | … |
| Sex | 82.90 | 79.82 | … |
| Smoking status,% | _ | _ | |
| Never | 20.44 | 20.72 | 0.09 |
| Past | 54.62 | 65.91 | _ |
| Current | 18.61 | 14.22 | _ |
| Level of diabetes | 30.11 | 20.44 | 0.004 |
| Body metabolic index, kg/m2 | 26.72 ± 5.93 | 28.55 ± 7.22 | 0.01 |
| Amount of the blood pressure, mm, hg | _ | _ | _ |
| Systolic pressure | 126.61 ± 18.52 | 127.90 ± 17.63 | 0.80 |
| Diastolic pressure | 89.11 ± 11.00 | 79.44 ± 18.62 | 0.92 |
| Lipid fractions level, mg/dL | _ | _ | _ |
| Total cholesterol level | 209.82 ± 17.81 | 207.44 ± 18.44 | 0.44 |
| LDL cholesterol | 140.33 ± 14.92 | 139.33 ± 12.92 | 0.43 |
| HDL cholesterol | 38.22 ± 8.71 | 39.22 ± 8.55 | 0.44 |
| Triglycerides | 146.55 ± 18.44 | 149.62 ± 69.55 | 0.40 |
Figure 3Age vs. systolic blood pressure.
Figure 4Cardiac abnormal events.
Figure 5HDL C content evaluation.
Figure 6TNF level evaluation.
Figure 7Detection rate of centripetal plaque.
Figure 8Diameter of narrowest lesion calculation.
Figure 9TG content vs. diastolic blood pressure.
Figure 10CRP content evaluations.
Figure 11Detection rate of eccentric plaque.
Figure 12LDL-C content evaluation.
Figure 13Performance metrics evaluation.